The Promise That Has Not Arrived
In December 2023, the FDA approved Casgevy (exagamglogene autotemcel) — the first CRISPR-based therapy ever authorized for clinical use in the United States. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, it offered something that had never existed before: a functional cure for sickle cell disease (SCD), a devastating blood disorder that affects approximately 100,000 Americans and millions more worldwide. The clinical data was remarkable. In pivotal trials, 97% of treated patients were free of the excruciating vaso-occlusive crises that define the disease for at least 12 consecutive months after treatment.
The medical community celebrated. Advocacy organizations declared a new era. Parents of children with sickle cell disease allowed themselves, for the first time, to imagine a life without emergency room visits, chronic pain, and the knowledge that their child's average life expectancy was roughly 54 years.
Two years later, the celebration has gone quiet.
As of early 2026, approximately 165 patients have received Casgevy in the United States. Out of 100,000. That is 0.165% of the eligible population — a fraction so small it barely registers on a chart. Vertex reported just $116 million in Casgevy revenue for 2025, a figure that fell dramatically short of the $300 million to $500 million Wall Street analysts had projected. The company's stock took a hit, and analysts quietly revised their forecasts downward.
The question is no longer whether Casgevy works. It does. The question is why a cure exists and almost nobody can get it.
The answer involves a $2.2 million price tag, a treatment process that consumes the better part of a year, a network of authorized treatment centers that leaves most patients hundreds of miles from care, an insurance system that was not designed to pay for cures, and a set of racial and economic inequities that the American healthcare system has never been particularly motivated to address.
How Casgevy Treatment Actually Works
To understand why access is so difficult, you first have to understand what the treatment demands of a patient. Casgevy is not a pill. It is not an infusion you receive at your local clinic. It is a months-long medical odyssey that requires uprooting your life.
Step 1: Evaluation and Referral (Weeks 1-4)
The patient must first be evaluated at one of roughly 50 authorized treatment centers (ATCs) in the United States. These are major academic medical centers — places like Children's National in Washington D.C., Emory in Atlanta, or UCSF — that have the specialized facilities, trained personnel, and regulatory clearances to administer the therapy. A primary care physician or hematologist must refer the patient, and the patient must meet eligibility criteria: they must have severe sickle cell disease with a history of vaso-occlusive crises.
Step 2: Stem Cell Mobilization and Collection (Weeks 4-8)
The patient receives a drug called plerixafor (Mozobil) to mobilize their hematopoietic stem cells from the bone marrow into the bloodstream. These CD34+ stem cells are then collected through apheresis — a process where blood is drawn, run through a machine that separates out the stem cells, and returned to the patient. Multiple apheresis sessions may be needed to collect enough cells. This phase alone requires the patient to be at or near the treatment center for extended periods.
Step 3: Manufacturing (6-12 Weeks)
The collected stem cells are shipped to a specialized manufacturing facility where the CRISPR-Cas9 editing takes place. Technicians use a guide RNA to direct the Cas9 protein to the BCL11A enhancer region in the stem cells. By disrupting this genetic switch, the cells are reprogrammed to produce fetal hemoglobin — a form of hemoglobin that is unaffected by the sickle cell mutation. Each batch is manufactured for a single patient. Quality control testing, which includes verifying editing efficiency and checking for off-target effects, takes weeks.
Step 4: Myeloablative Conditioning (1-2 Weeks)
This is the most physically grueling part of the process. Before the edited cells can be infused, the patient's existing bone marrow must be destroyed using high-dose busulfan chemotherapy — a process called myeloablative conditioning. This is the same type of conditioning used before traditional bone marrow transplants. The side effects are severe: nausea, hair loss, mucositis (painful inflammation of the mouth and gut lining), immunosuppression, and a significant risk of infertility. The patient is essentially left without a functioning immune system for a period of weeks.
The requirement for myeloablative conditioning is, by wide consensus, the single biggest clinical barrier to broader Casgevy adoption. Many patients — particularly older adults or those with existing organ damage from years of sickle cell crises — cannot safely undergo the procedure. Many more are simply unwilling to accept the risks, especially infertility in younger patients who want to have children.
Step 5: Infusion and Recovery (4-8 Weeks)
The edited stem cells are infused back into the patient intravenously. Over the following weeks, the cells engraft in the bone marrow and begin producing red blood cells that contain high levels of fetal hemoglobin. The patient remains hospitalized or under close monitoring for roughly four to six weeks during this engraftment period, as their immune system rebuilds. Infections during this window can be life-threatening.
Total Duration: 6-9 Months
From initial evaluation to discharge after engraftment, the entire Casgevy treatment process takes approximately six to nine months. During much of this time, the patient cannot work, must live near the treatment center, and needs a dedicated caregiver. For a single parent in rural Mississippi — which has one of the highest SCD prevalence rates in the country — the logistical burden is nearly impossible to bear.
The $2.2 Million Question
Casgevy's list price is $2.2 million per patient. This is the wholesale acquisition cost of the therapy itself. It does not include hospitalization, chemotherapy, apheresis, follow-up care, travel, or lost wages. When all associated medical costs are factored in, the total cost of Casgevy treatment has been estimated at $2.7 million to $3.0 million per patient.
Vertex has defended the price using the lifetime-value argument. The company estimates that the total lifetime healthcare cost for a patient with severe sickle cell disease — including hospitalizations, blood transfusions, medications, emergency room visits, and lost productivity — ranges from $1.6 million to $6 million. By this framing, Casgevy is not merely a treatment but a cost-saving investment.
The argument is not unreasonable in the abstract. But it collides head-on with reality. The American healthcare system does not pay for treatments on a lifetime-value basis. Insurance operates on annual budgets. A Medicaid program in Alabama or Georgia is not positioned to write a $2.2 million check today based on the promise of savings that will materialize over 30 years across a patient's lifetime — savings that will likely accrue to a different insurer, since patients change coverage regularly.
Who Actually Pays?
Roughly 60% of Americans with sickle cell disease are covered by Medicaid. This is not a coincidence. SCD disproportionately affects Black Americans, who are more likely to live in poverty, more likely to be covered by Medicaid, and more likely to live in states that historically underinvest in healthcare infrastructure. Medicaid reimbursement rates are substantially lower than private insurance rates, and many Medicaid programs have struggled to establish pathways for covering million-dollar one-time therapies.
Private insurers have also been slow to approve Casgevy. Prior authorization processes for gene therapies are notoriously complex, and some insurers have imposed additional requirements — such as documentation of multiple prior hospitalizations or failure of other treatments — that delay access by months. Several patient advocacy organizations have reported cases where insurers denied Casgevy coverage altogether, requiring lengthy appeals processes.
The CMS Outcomes-Based Model
In January 2024, the Centers for Medicare and Medicaid Services (CMS) announced a groundbreaking outcomes-based payment model for Casgevy and Lyfgenia (the other SCD gene therapy approved simultaneously). Under this model, state Medicaid programs can negotiate outcomes-based agreements with manufacturers, in which the full payment is contingent on the therapy meeting defined clinical benchmarks over time. If a patient does not achieve a sustained clinical response, the manufacturer provides a rebate.
The CMS model also includes a "cell and gene therapy access" framework that aims to make it easier for state Medicaid programs to cover these therapies. As of early 2026, approximately 14 states have signed on to participate, and negotiations with additional states are ongoing. The model has been praised as innovative, but critics point out that it still does not solve the fundamental logistical challenges — even if Medicaid will pay for the therapy, a patient still has to get to a treatment center and spend months there.
The Geography Problem
There are currently approximately 50 authorized treatment centers for Casgevy in the United States. These centers are concentrated in major metropolitan areas, primarily on the coasts and in the Southeast. This means that patients in rural areas — where a disproportionate share of SCD patients live — face enormous geographic barriers.
A 2024 analysis published in Blood Advances found that more than 40% of SCD patients in the United States live more than 100 miles from the nearest authorized treatment center. In states like Mississippi, Louisiana, Alabama, and South Carolina — where SCD prevalence is highest — the nearest ATC may be a five-hour drive away.
For a treatment that requires months of proximity to the center, distance is not a minor inconvenience. It is a structural barrier. Patients need to relocate temporarily, arrange childcare for other children, find housing near the hospital, and sustain themselves financially during a period when they cannot work. Many patients with sickle cell disease are already managing chronic pain, fatigue, and the cumulative organ damage that the disease inflicts over decades. Asking them to uproot their lives for half a year, while simultaneously undergoing chemotherapy, is asking more than many can give.
Some treatment centers have established housing assistance programs, and nonprofit organizations like the Sickle Cell Disease Association of America have created travel grant programs. But these are small-scale solutions to a systemic problem. There is no national infrastructure for supporting patients through the logistical demands of gene therapy.
The Racial Equity Dimension
It is impossible to discuss Casgevy's access crisis without confronting the racial dynamics embedded in it. Sickle cell disease overwhelmingly affects Black Americans. Approximately 1 in 365 Black or African American babies is born with SCD, compared to roughly 1 in 16,300 Hispanic American births and negligible rates in white populations. This is because the sickle cell trait evolved as a protective adaptation against malaria in populations of sub-Saharan African, Mediterranean, Middle Eastern, and South Asian descent.
The history of sickle cell disease research and treatment in the United States is a history of neglect. For decades, SCD received a fraction of the research funding allocated to comparably severe diseases that primarily affect white populations. Cystic fibrosis, which affects roughly 40,000 Americans (compared to SCD's 100,000), has historically received three to ten times more research funding per patient. The Cystic Fibrosis Foundation's model of dedicated care centers and aggressive drug development has produced a pipeline of effective treatments, including Trikafta, which has transformed outcomes for CF patients. No equivalent infrastructure exists for sickle cell disease.
This disparity extends into the present. The fact that a cure exists and is functionally inaccessible to most patients — patients who are predominantly Black, predominantly low-income, and predominantly covered by Medicaid — is not a new story in American medicine. It is the same story, told with a new technology.
Civil rights organizations and patient advocacy groups have been increasingly vocal about this dynamic. In 2025, a coalition of organizations including the NAACP, the Sickle Cell Disease Association of America, and the National Alliance for Sickle Cell Centers called on Congress to fund a dedicated national access program for sickle cell gene therapies. As of early 2026, no such program has been established.
Dr. Alexis Thompson, a hematologist at Children's Hospital of Philadelphia who has been a leading voice on SCD equity, has described the situation plainly: "We have a cure. We have patients who are dying. And we have a system that is structured in a way that the cure cannot reach the patients. If sickle cell disease primarily affected white children, this would be treated as an emergency."
Lyfgenia: A Cautionary Comparison
Casgevy is not the only gene therapy approved for sickle cell disease. On the same day in December 2023, the FDA also approved Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio. Lyfgenia uses a lentiviral vector rather than CRISPR to introduce a modified hemoglobin gene (HBB-T87Q) into the patient's stem cells. Its list price is $3.1 million — nearly $1 million more than Casgevy.
Lyfgenia's commercial performance has been even worse than Casgevy's. Bluebird bio, which went public in 2013 and was once valued at over $10 billion, has seen its market capitalization collapse to under $200 million. The company reported fewer than 20 patients treated with Lyfgenia in 2025, generating minimal revenue. In late 2025, bluebird bio announced a strategic restructuring, and analysts have openly questioned whether the company can survive as an independent entity.
The Lyfgenia story is both a cautionary tale and a bellwether. It demonstrates that the challenges facing Casgevy are not specific to one company or one technology — they are structural features of the gene therapy ecosystem. The treatment process for Lyfgenia is similar to Casgevy's (stem cell collection, ex vivo editing, myeloablative conditioning, infusion), the price is comparable, the authorized treatment centers overlap, and the same patient population is affected.
If anything, Lyfgenia faces an additional headwind: in clinical trials, a small number of patients developed hematologic malignancies (blood cancers) that may have been related to the lentiviral vector insertion. The FDA added a black box warning to the label, which has further dampened physician and patient enthusiasm relative to Casgevy, which has not shown the same safety signal.
The failure of both therapies to reach patients at scale suggests that the problem is not one of clinical efficacy or even pricing (though pricing is a major factor). The problem is the entire model of ex vivo gene therapy as currently practiced — a model that is inherently complex, slow, resource-intensive, and geographically concentrated.
What $116 Million in Revenue Actually Means
To put Casgevy's commercial performance in perspective: Vertex Pharmaceuticals is a company that generates approximately $9 billion per year from its cystic fibrosis franchise (Trikafta/Kaftrio). Casgevy's $116 million in 2025 revenue represents roughly 1.3% of the company's total revenue. Initial analyst projections had estimated $2 billion to $4 billion in peak annual Casgevy revenue within five to seven years of launch. Those projections are now being revised to $500 million to $1.5 billion, with many analysts pushing peak revenue further into the future.
The revenue shortfall is not because patients do not want the treatment. Surveys consistently show that a significant majority of SCD patients are interested in gene therapy. A 2025 survey published in JAMA Network Open found that 68% of adults with SCD expressed willingness to undergo Casgevy treatment if logistical and financial barriers were removed. The demand exists. The delivery system does not.
For Vertex, which has a diversified revenue base, Casgevy's slow ramp is disappointing but not existential. For the gene therapy field as a whole, the implications are more concerning. If the first CRISPR therapy — backed by two well-resourced companies, treating a relatively common genetic disease, with outstanding clinical data — cannot achieve meaningful commercial scale, what does that mean for future gene therapies targeting rarer diseases?
What Needs to Change
The Casgevy access crisis is not a problem with a single solution. It is a problem with multiple interlocking causes, each of which requires its own intervention. But several paths forward are becoming clear.
More Authorized Treatment Centers
Fifty ATCs for 100,000 patients is insufficient, particularly given the geographic concentration of SCD in the Southeast. Vertex and CRISPR Therapeutics have stated that they are working to certify additional centers, and the company has invested in training programs for hematologists and transplant physicians at community hospitals. The goal should be at least 80 to 100 centers, with particular emphasis on states with high SCD prevalence: Mississippi, Louisiana, Alabama, Georgia, South Carolina, and Texas.
The challenge is that certifying a new ATC is not trivial. Centers must have bone marrow transplant capabilities, apheresis equipment, cleanroom facilities for cell handling, and personnel trained in the specific protocols for Casgevy administration. Building this capacity takes years, not months.
Simplified Treatment Protocols
The six-to-nine-month treatment timeline is a direct result of the ex vivo approach — the need to collect cells, ship them for manufacturing, wait for editing and quality control, and then condition the patient before reinfusion. Any reduction in this timeline would materially improve access.
Several innovations are being explored. Point-of-care manufacturing — editing cells at the treatment center rather than shipping them to a centralized facility — could compress the manufacturing phase from 12 weeks to 2-4 weeks. Vertex has announced pilot programs exploring decentralized manufacturing models. Additionally, reduced-intensity conditioning regimens that avoid full myeloablative chemotherapy are being studied in clinical trials, which would make the treatment tolerable for a wider range of patients, including older adults and those with organ damage.
In Vivo Alternatives
The most transformative solution would be to eliminate the ex vivo process entirely. In vivo gene editing — delivering the CRISPR machinery directly into the patient's body — would turn a months-long hospital ordeal into a one-time injection. No stem cell collection. No chemotherapy. No months of recovery.
This is not science fiction. Several companies are actively pursuing in vivo approaches for SCD:
- Intellia Therapeutics is developing lipid nanoparticle-delivered CRISPR therapies that target cells in the liver. Their lead program, NTLA-2001 for transthyretin amyloidosis, has demonstrated successful in vivo gene editing in humans.
- Beam Therapeutics is working on in vivo base editing approaches for SCD that would use a single infusion to edit the HBB gene in hematopoietic stem cells without the need for myeloablative conditioning.
- Editas Medicine and several academic groups are exploring lipid nanoparticle and virus-like particle delivery systems that could target bone marrow stem cells directly.
The technical challenge is significant — delivering editing machinery specifically to hematopoietic stem cells in vivo is far harder than targeting the liver, which naturally accumulates lipid nanoparticles. But progress is being made, and multiple programs are expected to enter clinical trials in 2026 and 2027.
If successful, in vivo editing for SCD could reduce the cost of treatment from millions of dollars to potentially hundreds of thousands or less, eliminate the need for specialized transplant centers, and make the therapy accessible at any hematology clinic. This would be the true revolution — not just a cure, but a cure that patients can actually reach.
Insurance and Payment Reform
The CMS outcomes-based model is a start, but more structural reform is needed. Proposals under discussion include:
- Amortized payment models: Spreading the cost of gene therapy over multiple years (e.g., $220,000 per year for 10 years) rather than requiring a single lump-sum payment, which better aligns with insurance budgeting cycles
- Federal reinsurance pools: Creating a dedicated federal fund to backstop state Medicaid programs for high-cost gene therapies, similar to how the federal government supports disaster insurance
- Mandatory coverage requirements: Legislation requiring all Medicaid programs to cover FDA-approved gene therapies for sickle cell disease, removing the state-by-state patchwork that currently exists
- Travel and logistics support: Federal funding for patient transportation, temporary housing, and caregiver support during treatment — costs that are not covered by the therapy price but are essential for access
Community Engagement and Trust-Building
Finally, any access strategy must contend with the issue of trust. Black Americans have well-documented and historically justified reasons to distrust the medical establishment. From the Tuskegee syphilis study to documented disparities in pain management for Black patients, the relationship between the sickle cell community and the healthcare system is complex. Gene therapy — which involves editing a patient's DNA — touches particularly sensitive nerves.
Building trust requires sustained investment in community engagement, transparent communication about risks and benefits, inclusion of SCD patients and community leaders in treatment center advisory boards, and the recruitment of Black physicians and genetic counselors who can build relationships with the patient community. Several ATCs have begun this work, but it is slow, resource-intensive, and cannot be shortcut.
The Bigger Picture
Casgevy's access crisis is a microcosm of a larger tension in modern medicine. Biotechnology has reached the point where it can cure diseases that were previously lifelong sentences. But the systems that deliver healthcare — the insurance models, the hospital infrastructure, the geographic distribution of specialized care, the economic realities of patients' lives — were not designed for cures. They were designed for chronic disease management, for pills taken daily, for annual treatments administered at local clinics.
Gene therapy breaks this model. And until the model is rebuilt, the gap between what is medically possible and what is actually accessible will continue to widen. Casgevy works. The science is settled. The engineering is proven. What remains unsettled is whether the United States can build a healthcare delivery system that matches the ambition of its science.
For the 100,000 Americans with sickle cell disease — the vast majority of whom are Black, many of whom are poor, most of whom live far from the centers that could cure them — this is not an abstract policy question. It is their lives.
Sources & Further Reading
- Vertex Pharmaceuticals 2025 Annual Report and Q4 Earnings Call — Casgevy revenue figures and treatment center data
- CMS Cell and Gene Therapy Access Model — Outcomes-based Medicaid payment framework
- Kanter, J. et al. "Geographic access to authorized treatment centers for sickle cell gene therapy." Blood Advances (2024).
- Lubeck, D. et al. "Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease." JAMA Network Open (2019).
- FDA Approval of Casgevy (December 2023) — Original approval announcement
- Fitzhugh, C.D. et al. "Patient attitudes toward gene therapy for sickle cell disease." JAMA Network Open (2025).
- Power-Hays, A. and McGann, P.T. "When actions speak louder than words — racism and sickle cell disease." New England Journal of Medicine (2020).
- Sickle Cell Disease Association of America — Gene Therapy Resources
- bluebird bio 2025 Annual Report — Lyfgenia commercial performance data
- Intellia Therapeutics pipeline updates — In vivo CRISPR editing programs, intelliatx.com
Last updated: March 2026.
